( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Raed Aqel MD.*, Mohanad Saleh MD and Wafa Jubeh R. N.


Background: Cardiac resynchronization therapy (CRT) with and without automatic implantable cardioverter-defibrillators (AICDs), AICDs have been recommended as class1A recommendation for a certain subset of patients with Congestive heart failure with reduced ejection fraction (CHFrEF) based on multiple major trials that showed improved mortality and morbidity with these devices, however this comes at great cost which might be unaffordable in some health systems, LCZ696 in previous publication showed improvement in ejection fraction, in this study we for the first time showed some of the cost savings this medication had contributed to by reducing the need for such devices. Materials & Methods: A chart review of patients placed on LCZ696 for clinical purposes over 36 months between 2016 and 2018. All follow-up visits were analyzed. Quality of life-based on New York Heart Association (NYHA) classification was recorded. All hospital admissions, deaths, labs, echocardiograms were recorded. Length of the study was 3months- 36 months (mean of 16 months), all patients whose charts were reviewed, signed an informed consent form allowing for this charts review. Results: 180 charts were reviewed; mean follow-up was 16 months, 14 patients (8%) died during follow-up. 29 patients(16%)stopped the medication, patients receiving LCZ 696 showed 43% improvement in EF and 41% improvement in NYHA class.(125) patients had an ejection fraction of less than 35%on initial presentations, of those (73) patients (64%) improved their ejection fraction to above 35%, and 12 patients (10%) did not have a follow-up echocardiogram, 5 patients (3%) lost follow-up. Conclusion: use of LCZ696 did improve not only quality of life but also ejection fraction resulting in a reduction in the need of devices with subsequent major health cost savings, based on our knowledge this result is the first time to be measured statistically and reported.

Keywords: Sacubitril / valsartan, heart failure, angiotensin receptor-neprilysin inhibitors (ARNIs), NOTE: the guidelines of the STROBE Statement have been adopted in this study.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.


    FEBRUARY 2024 issue has been successfully launched on 1 FEBRUARY 2024.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2024 Issue has been Published, Kindly check it on

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia